ストックスクリーナーアプリを入手
1.69
8.33%
0.13
アフターアワーズ：
1.68
-0.01
-0.59%
前日終値:
$1.56
開ける：
$1.58
24時間の取引高:
912.36K
Relative Volume:
1.68
時価総額：
$63.08M
収益：
-
当期純損益:
$-40.56M
株価収益率:
-1.4444
EPS:
-1.17
ネットキャッシュフロー:
$-35.28M
1週間 パフォーマンス:
+22.46%
1か月 パフォーマンス:
+42.02%
6か月 パフォーマンス:
-22.12%
1年 パフォーマンス:
-41.72%
1日の値動き範囲:
$1.58
$1.76
1週間の範囲:
$1.38
$1.76
52週間の値動き範囲:
$0.8505
$4.42
Pds Biotechnology Corporation Stock (PDSB) Company Profile
名前
Pds Biotechnology Corporation
セクター
電話
800-208-3343
住所
303A COLLEGE ROAD EAST, PRINCETON
PDSB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.69 | 63.08M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-01 | 開始されました | B. Riley Securities | Buy |
| 2021-06-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 開始されました | Alliance Global Partners | Buy |
| 2020-03-09 | 開始されました | Noble Capital Markets | Outperform |
| 2019-10-24 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Pds Biotechnology Corporation (PDSB) 最新ニュース
Northern Trust Corp Trims Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial By Investing.com - Investing.com South Africa
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - Barchart.com
Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus - TradingView
PDSB: PDS Biotechnology Releases Promising Results from Versamune HPV Studies | PDSB Stock News - GuruFocus
PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO - TipRanks
PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial - Investing.com
Clinical Trial Breakthrough: PDS Biotech Achieves 30-Month Survival in Advanced Head and Neck Cancer Patients - Stock Titan
PDS Biotechnology files to sell 9.82M shares of common stock for holders - MSN
PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Sh - GuruFocus
PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDS - GuruFocus
PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDSB Stock News - GuruFocus
Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to “Hold” - Defense World
PDS Biotechnology Corporation (PDSB)’s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial - Insider Monkey
Transcript : PDS Biotechnology CorporationSpecial Call - marketscreener.com
Q2 EPS Estimates for PDS Biotechnology Raised by B. Riley - Defense World
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
PDS Biotech reports extended survival in HPV cancer study - Investing.com Australia
PDS Biotech reports extended survival in HPV cancer study By Investing.com - Investing.com India
PDS Biotechnology Reports Promising Overall Survival Data for Versamune® HPV Combined with Pembrolizumab in HPV16-Positive Head and Neck Cancer - Nasdaq
PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential By Investing.com - Investing.com South Africa
PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential - Investing.com
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase - The Manila Times
PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript - MSN
PDS Biotech outlines continued VERSATILE 003 Phase 3 expansion while advancing HPV16-positive head and neck cancer strategy - MSN
Raymond James Financial Inc. Takes $26,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Reports Q1 2025 Progress and Financials - TipRanks
PDS Biotech advances Phase 3 trial, reports Q1 financials By Investing.com - Investing.com Nigeria
PDS Biotechnology: Q1 Earnings Snapshot - Midland Daily News
EMV Capital portfolio company PDS Biotech advances cancer trial - Proactive Investors
PDS Biotech advances Phase 3 trial, reports Q1 financials - Investing.com Australia
Earnings call transcript: PDS Biotech’s Q1 2025 results show reduced losses - Investing.com
Transcript : PDS Biotechnology Corporation, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
PDSB Advances with Phase 3 Trial for Versamune HPV Therapy | PDS - GuruFocus
PDS Biotechnology Corporation Initiates VERSATILE-003 Phase 3 Trial and Announces Abstracts Selected for ASCO 2025 - Nasdaq
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update - TradingView
PDS Biotechnology (PDSB) Expected to Announce Earnings on Wednesday - Defense World
Pds Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
PDS Biotechnology Unveils Promising Flu Vaccine Data - TipRanks
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting - The Manila Times
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results - TradingView
Marshall Wace LLP Has $64,000 Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Renaissance Technologies LLC Acquires 76,800 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
THE CANADIAN INTERNATIONAL TRADE TRIBUNAL TERMINATES ITS PRELIMINARY INJURY INQUIRY IN RESPECT OF TIDEWATER RENEWABLES LTD.'S COUNTERVAILING (ANTI-SUBSIDY) AND ANTI-DUMPING DUTY COMPLAINT RELATING TO I - The Globe and Mail
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Call Transcript - MSN
PDS Biotechnology Enters $20M Securities Purchase Agreement - TipRanks
Pds Biotechnology Corporation (PDSB) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):